Detecting and Absolutely Quantifying Patient-specific Neoantigens from Limited Input of Biopsy Sample — An Integrated Pipeline for Neoantigen-targeted Cancer Treatments February 28, 2022 Read More »
Identifying and Quantifying Neoantigens derived from Human endogenous retroviruses (HERVs) — A new class of targets to expand the benefits of cancer immunotherapy. January 29, 2022 Read More »
Our clinical proteomics pipeline enabling personalized cancer therapeutics, reported by numerous media March 15, 2021 Read More »
14 May 2025
